Antigen Probe Arrays for SLE Diagnosis Using Machine Learning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for systemic lupus erythematosus (SLE) lack specificity and sensitivity, particularly in distinguishing active disease from non-active states and differentiating SLE from other autoimmune disorders, due to the non-specific nature of anti-nuclear antibodies (ANA) and the complexity of autoantibody profiles.
Innovation Solution
Development of antigen probe arrays and machine learning-based classifiers using specific protein, peptide, polynucleotide, and oligonucleotide antigens, such as ssDNA, Sm, DNAse I, Histone III-S, Ro52, U1 snRNP, Collagen III, Apo-SAA, and Oligo21, to analyze antibody reactivity patterns in patient samples, enabling accurate diagnosis and monitoring of SLE.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ANA testing is used for SLE diagnosis, then the diagnosis can be performed, but the specificity is poor due to false positives in healthy population
Solution Approach 1:
The patent segments the ANA testing process into multiple stages: first performing a broad ANA screening, then applying machine learning-based classification algorithms that analyze multiple parameters (antibody titers, reactivity patterns, spectral profiles) to differentiate true SLE cases from false positives in the healthy population, thereby improving specificity while maintaining sensitivity
Solution Approach 2:
The invention changes the parameters used for diagnosis by transitioning from simple binary ANA positive/negative results to multi-dimensional parameter analysis including antibody titers at different dilutions (1:80, 1:160, 1:320), reactivity patterns across multiple nuclear compartments, and machine learning-derived classification scores, enabling more precise differentiation between SLE patients and ANA-positive healthy individuals
2Measurement precision
If multiple antigen-specific ANA tests are performed to improve specificity, then false positives are reduced, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent merges multiple antigen-specific ANA tests into a single automated machine learning-based classification system that simultaneously analyzes reactivity patterns across numerous antigens (histones, DNA, nucleosomes, viral antigens, transcription factors) and integrates multiple parameters (titers, spectral profiles, reactivity patterns) to generate a unified diagnostic classification, reducing procedural complexity while maintaining high specificity
Solution Approach 2:
The invention replaces the manual, step-by-step mechanical process of performing multiple separate antigen-specific ANA tests with an automated machine learning-based classification algorithm that computationally analyzes the same data, automatically differentiating SLE from other conditions without requiring manual interpretation of each individual test result
3Ease of operation
If traditional ANA testing methods are used, then the diagnostic process is simple, but the ability to distinguish active disease from non-active states is poor
Solution Approach 1:
The patent performs preliminary action by collecting and analyzing multiple parameters simultaneously during the initial ANA testing process, including antibody titers at multiple dilutions, reactivity patterns across different nuclear compartments, and spectral profiles, which are then fed into machine learning algorithms to extract disease activity information without requiring additional separate testing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach provides highly sensitive and specific assays for diagnosing SLE, with sensitivity up to 98% and specificity up to 59%, effectively differentiating SLE patients from healthy controls and ruling out false positives, and monitoring disease activity with high accuracy.
Implementation Method 1
determining the reactivity of antibodies in the sample to at least four antigens selected from the group consisting of ssDNA, Sm, DNAse I, Histone III-S, Ro52 (TRIM21), U1 snRNP, Collagen III, Apo-SAA, H2a and Oligo21
Data Source
AI summary
Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.